Delivery Order SPE2DB22D2211-SPE2DB25FSDWP
- Not listed
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 21, 2025, with completion scheduled for September 12, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody immunosuppressant medication used primarily to treat systemic lupus...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injector on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a $3,082.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors, with an ultimate completion date of August 26, 2025. This competitively awarded contract, issued on August 5, 2025, represents a child delivery order under a larger contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on July 24, 2025, with a completion date of August 14, 2025. This firm fixed price, competitively awarded contract requires delivery to the company's headquarters location in Conshohocken, Pennsylvania. BENLYSTA (belimumab) is a monoclonal antibody used in the treatment of systemic lupus erythematosus, reflecting the breadth of specialty pharmaceutical...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDWPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on August 28, 2025, with completion anticipated by September 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune conditions, representing specialized pharmaceutical procurement to support military and federal healthcare requirements. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen leverages this comprehensive global contract vehicle to supply a broad range of medications and medical supplies supporting Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. The company's extensive portfolio of federal awards demonstrates its capability to fulfill complex pharmaceutical supply requirements across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.5k | 8/28/25 |